Important patient safety considerations include: GLP-1 receptor agonists are currently licensed only for type 2 diabetes and, for specific products, weight managementnot for neurological conditions Common side effects include nausea, vomiting, diarrhoea, and constipation, which usually improve over time Patients should seek urgent medical help for symptoms suggestive of pancreatitis (severe, persistent abdominal pain, often radiating to the back, with or without vomiting) Gallbladder problems including gallstones and inflammation may occur Risk of hypoglycaemia is increased when used with insulin or sulfonylureas Diabetic retinopathy complications may occur with semaglutide, particularly with rapid improvement in blood glucose control [26] [27] Severe gastrointestinal side effects may lead to dehydration and acute kidney injury These medications are not recommended during pregnancy or breast-feeding [25] [1] Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)

Understanding these challenges helps contextualize the potential role of medications like tirzepatide in comprehensive disease management
:
This conversion happens primarily in the gut and liver after oral ingestion
The data tells a more complicated and frankly more impressive story
Finally, we conducted subgroup analyses by sex and obesity status, demonstrating generally consistent associations across strata, and we implemented an exposure lag period to reduce potential reverse causality, collectively strengthening the credibility of the observed associations